You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

50 Results
Drug
Other Name(s): Mozobil®
Jun 2019
Drug
Other Name(s): Oncaspar®
Dec 2022
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Funding:
New Drug Funding Program
    Pembrolizumab - In Combination with Platinum and Pemetrexed for First Line Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Aug 2023
Regimen
Cancer Type:
Hematologic, 
Lymphoma - T-cell
Intent: Palliative
Funding:
New Drug Funding Program
    Pralatrexate - Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Sep 2023
Drug
Other Name(s): Folotyn®
Dec 2021
Regimen
Intent: Adjuvant, Curative
Funding:
New Drug Funding Program
    Trastuzumab (Biosimilar) - Adjuvant Treatment for Breast Cancer
Sep 2022
Regimen
Intent: Palliative
Funding:
New Drug Funding Program
    Pembrolizumab - Locally Recurrent Unresectable or Metastatic Triple Negative Breast Cancer
Sep 2023
Drug
Other Name(s): Polivy™
Dec 2022
Regimen
Intent: Neoadjuvant
Funding:
New Drug Funding Program
    Pembrolizumab - Previously Untreated High-Risk Early-Stage Triple Negative Breast Cancer
Sep 2023
Regimen
Intent: Neoadjuvant
Funding:
New Drug Funding Program
    Pembrolizumab - Previously Untreated High-Risk Early-Stage Triple Negative Breast Cancer
Feb 2023
Regimen
Intent: Neoadjuvant
Funding:
New Drug Funding Program
    Pembrolizumab - Previously Untreated High-Risk Early-Stage Triple Negative Breast Cancer
Sep 2023
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Lymphoblastic (ALL)
Intent: Curative
Funding:
ODB - General Benefit
    mercaptopurine
ODB - General Benefit
    prednisone
ODB - General Benefit
    methotrexate - oral tablets
New Drug Funding Program
    Pegaspargase (Outpatient) - Adult Acute Lymphoblastic Leukemia (ALL) Lymphoblastic Lymphoma Mixed or Biphenotypic Leukemia
New Drug Funding Program
    Calaspargase Pegol (Outpatient) - Newly Diagnosed Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma or Mixed_Biphenotypic Leukemia
Dec 2024

Pages